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Purpose: The RECOMMEND study (NCT02364284; D4280R00005) assessed the clinical 
management patterns and treatment outcomes associated with initial antibiotic therapy (IAT; 
antibiotics administered ≤48 hours post-initiation of antibiotic therapy) for health care-associated 
infections across five countries.
Patients and methods: Data were collected from a retrospective chart review of patients aged 
≥18 years with health care-associated complicated intra-abdominal infection (cIAI). Potential 
risk factors for IAT failure were identified using logistic regression analyses.
Results: Of 385 patients with complete IAT data, bacterial pathogens were identified in 270 
(70.1%), including Gram-negative isolates in 221 (81.9%) and Gram-positive isolates in 92 
(34.1%). Multidrug-resistant (MDR) pathogens were identified in 112 patients (41.5% of patients 
with a pathogen identified). IAT failure rate was 68.3% and in-hospital mortality rate was 40.8%. 
Multivariate regression analysis demonstrated three factors to be significantly associated with 
IAT failure: patients admitted/transferred to the intensive care unit during index hospitalization, 
isolation of an MDR pathogen and previous treatment with β-lactam antibiotics.
Conclusion: We reveal the real-world insights into the high rates of IAT failure and mortality 
observed among patients with cIAI. These data highlight the challenges associated with choos-
ing IAT, the impact of MDR pathogens on IAT outcomes and the importance of tailoring IAT 
selection to account for local epidemiology and patient history.
Keywords: complicated intra-abdominal infection, health care associated, initial antibiotic 
treatment, clinical outcome, real-world treatment patterns
Introduction
Complicated intra-abdominal infections (cIAIs) occur when the infectious process of 
an intra-abdominal infection (IAI) extends beyond the limits of one organ, causing 
localized or diffuse infection of the peritoneum that is usually polymicrobial in nature.1 
The bacterial flora that comprise the infection are generally dependent on the specific 
location of the site of the perforation of the gastrointestinal tract in community-acquired 
cIAI.2 Health care–associated cIAIs frequently result from previous intra-abdominal 
surgery, and therefore, the nature of the infecting nosocomial pathogen is typically 
defined by a combination of the site of the operation and the hospital.2 cIAIs that occur 
in a health care-associated setting (hospital-acquired or acquired in another health 
care setting) are generally associated with higher mortality rates than community-
acquired IAIs. This increased mortality is due, in part, to the likely poorer underlying 
health status of patients in health care facilities and the impact of comorbidities on 
prognosis.3 In addition, patients acquiring cIAI after surgery may have nutritional 
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deficiency, altered intestinal flora and immune deficiency 
that also impact on prognosis.4 There is also the potential for 
the involvement of a broader spectrum of microorganisms in 
health care-associated infection,5 with an increased likelihood 
that the causative pathogens are multidrug resistant (MDR).6 
Pathogens typically isolated from health care-associated 
cIAIs are Gram-negative organisms, most commonly Esch-
erichia coli, Klebsiella pneumoniae and Pseudomonas aeru-
ginosa; Gram-positive species, namely, Enterococcus spp.; 
and anaerobic species.7 The increasing global prevalence of 
MDR pathogens in this setting, in particular, the continu-
ing spread of extended-spectrum β-lactamase–producing 
Gram-negative Enterobacteriaceae, is a major concern for 
the treatment of cIAIs.8–10
Management of cIAI requires both timely surgical 
source control and empirical initial antibiotic therapy (IAT), 
followed by a switch to a more specific antibiotic regimen 
based on bacterial culture results.6,11,12 To provide adequate 
coverage, IAT typically incorporates broad-spectrum anti-
biotics, sometimes in combination.12 However, resistance 
rates in cIAI isolates are constantly changing and are also 
subject to regional variation; thus, local epidemiology must 
be accounted for to ensure that this empirical approach covers 
the relevant pathogens and does not contribute further to the 
development of antibiotic resistance.9,10,13–15
In severe health care-associated infections, delayed IAT 
and the administration of inappropriate antibiotics have both 
been linked with IAT failure, increased morbidity and mor-
tality and an increased burden on health care resources.16–19 
There is a need, therefore, to gain a better understanding of 
the treatment patterns and risk factors associated with IAT 
failure, and the impact of IAT failure on patients in a real-
world setting. To date, very few studies have looked, on an 
international scale, at the outcome of IAT in patients with 
health care-associated cIAI. Clinical trial eligibility criteria 
often restrict the inclusion of patients with comorbid diseases, 
so their findings may not be representative of real-world 
patients.20,21 Furthermore, published observational studies 
have addressed mixed patient populations predominantly 
with community-acquired infections, rather than health care-
associated infections.5,22
The  RECOMMEND s tudy  (NCT02364284 , 
D4280R00005) involved a comprehensive review of the 
medical records of patients with health care-associated cIAI, 
complicated urinary tract infection (cUTI) and nosocomial 
pneumonia (NP) across five different countries. The aim of 
the study was to evaluate the treatment patterns and clinical 
outcomes among these patients, including an assessment 
of the IAT outcomes and risk factors associated with IAT 
failure. Analyses relating to patients with cIAI are reported 
here.
Patients and methods
study design
RECOMMEND was an international, retrospective, multi-
center, non-interventional cohort study based on a retrospec-
tive chart review of hospitalized adult patients with health 
care-associated cIAI, cUTI or NP from Brazil, France, Italy, 
Russia and Spain, between July 1, 2013 and June 30, 2014. 
The study was designed and performed in accordance with 
the ethical principles of the Declaration of Helsinki. The 
study was consistent with the sponsor’s policy on bioethics, 
the harmonized tripartite guideline E6(R1) from the Interna-
tional Conference on Harmonization, Good Clinical Practice 
and applicable regulatory requirements. The study protocol 
was reviewed and approved by an ethics committee (EC) or 
an institutional review board (IRB) at each site, except in 
France, where this is not required for retrospective studies, 
and Spain, where the national regional regulatory agency 
evaluated and classified the study in addition to EC approv-
als. The names of the ECs and IRBs providing their approval 
for the conduct of this study can be found in Table S1. Site 
investigators were responsible for obtaining informed consent 
from the patient or their legal representative in accordance 
with the local regulations.
Data were collected in an electronic case report form 
based on patient medical records covering the patient from 
diagnosis to 30 days’ post-discharge, death, loss to follow-up 
or the end of the study period (December 31, 2014) if not 
discharged by the end of the study.
Patients
For inclusion in the current analysis, patients had to be 
aged ≥18 years and have a clinical diagnosis of health care-
associated cIAI requiring surgical intervention as previously 
defined,21 with evidence of involvement of more than one 
organ causing peritonitis, and parenteral antibiotic therapy 
during the hospital stay beyond the 24-hour regimen asso-
ciated with surgery. Health care–associated infection was 
defined as hospital acquired (developed ≥48 hours after 
hospital admission) or acquired in another health care setting, 
including hospitals, nursing homes, long-term care facili-
ties or hemodialysis clinics, ≤3 months prior to or during 
in-patient admission. Patients were excluded from the study 
if they had taken part in any clinical trial during the patient 
selection or follow-up period.
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Patients were identified using the ICD-10th revision codes 
or diagnosis-related group codes from the hospital discharge 
records, the health care-associated infection registry or other 
site-specific sources. Inclusion and exclusion criteria were 
applied to the corresponding medical charts and the final 
selection of eligible patients was at the discretion of the 
investigator, applying the criteria used in routine practice 
to identify patients with complicated infections. Each site 
could accrue a maximum of 40 patients per type of infection.
study measures
The primary objective of the study was to document the asso-
ciation of clinical outcomes with IAT (defined as all antibiotic 
agents administered during the 48 hours post-initiation of 
antibiotic therapy) and determine the factors associated with 
IAT success and failure. Success was defined as discontinua-
tion of IAT, including de-escalation or streamlining, because 
of clinical cure or improvement, with no further need for an 
antibiotic; or a switch to oral antibiotic; and no readmission 
due to the same infection within 30 days of discharge. Fail-
ure was defined as discontinuation of the antibiotic regimen 
for reasons other than cure, de-escalation or streamlining; 
a change in IAT due to perceived clinical failure; a dose 
increase or addition of another antibiotic beyond 48 hours 
of treatment; the requirement of an additional source control 
procedure performed >48 hours post-IAT; in-hospital death 
of any cause; or readmission due to recurrence of the same 
infection within 30 days of discharge. In cases in which 
there was insufficient information to conclude whether the 
IAT outcome was a failure or a success, an indeterminate 
outcome was concluded. Data were collected for IAT and up 
to four additional lines of antibiotic treatment following IAT. 
A new line of antibiotic treatment was defined as any change 
occurring after 48 hours of initiation of antibiotic therapy, 
including discontinuation, an increase in dose, a switch to 
oral therapy or the addition of a new antibiotic.
Additional information captured from medical records 
comprised baseline details relating to patients, pathogens 
and sites, including patient age, sex, comorbidity burden, 
pathogen type and the presence of MDR pathogens. To be 
classified as MDR, pathogens had to display resistance to 
at least one antibiotic in a minimum of three of any of the 
following drug classes: aminoglycosides, chloramphenicol, 
carbapenems, cephalosporins, glycylcycline, penicillins ± 
β-lactamase inhibitors, quinolones, tetracyclines, macro-
lides or streptogramins for all pathogens; or glycopeptides, 
oxazolidinones and lipopeptides for Gram-positive patho-
gens; or mono-bactams for Gram-negative pathogens; or 
nitroimidazole for anaerobic pathogens. The incidence of 
IAT failure, in-hospital mortality rate, mortality rate at 30 
days’ post-discharge, incidence of hospital readmissions 
within 30 days’ post-discharge, incidence of secondary 
infections, hospital length of stay, and total number of 
days on IAT and four additional lines of antibiotic treat-
ment were also noted. Details of treatment were recorded, 
including antibiotic type(s), monotherapy or a combination 
of antibiotics, and the physician-reported reason for ending 
treatment.
statistical analyses
All variables were reported using descriptive statistics, and 
data were analyzed overall and by country. The association 
of IAT failure with potential risk factors (characteristics of 
patients [demographic and clinical], pathogens, sites and 
treatment) was explored using univariate and multivariate 
logistic regression analyses. For the regression analyses, 
indeterminate outcomes were grouped with treatment 
successes. The multivariate regression analysis included 
variables from the univariate analysis with P<0.25 as the 
potential confounders. ORs, corresponding 95% CIs and 
P-values were calculated. All analyses were performed by 
Quintiles using SAS® (SAS Institute Inc., Cary, NC, USA) 
version 9.4.
Results
Patient demographic and clinical 
characteristics
Data from 26 hospital sites across the five participating 
countries were collected (Brazil, n=4; France, n=6; Italy, 
n=6; Russia, n=4; Spain, n=6). Across all three indications 
of interest, 1,708 potential patients were identified, and 
1,321 patients were enrolled based on the inclusion criteria 
for each indication and patient consent, where applicable 
(not required in Spain). Complete start and stop records for 
IAT were available for 1,244 patients (cIAI, n=385; cUTI, 
n=408; NP, n=451).
In total, 385 (30.9%) out of 1,244 patients were included 
with health care-associated cIAI as their index infection, with 
a mean (SD) age at hospital admission of 64.4 (15.7) years 
and a relatively even split of male to female patients (56.4% 
male overall), as shown in Table 1.
The majority (62.1%) were enrolled with hospital-
acquired cIAI. The most common cIAI conditions (≥10% of 
patients) were secondary peritonitis (37.4%), intra-abdominal 
abscess (30.4%) and cholecystitis (16.4%). The mean (SD) 
Deyo-Charlson comorbidity score (DCCS) was 2.4 (2.5), 
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Table 1 Patient demographic and clinical characteristics at index hospitalization, overall and by country
Parameters Brazil 
(n=89)
France 
(n=65)
Italy 
(n=68)
Russia 
(n=74)
Spain 
(n=89)
Total 
(N=385)
age, years       
Mean (sD) 57.9 (17.4) 67.3 (12.4) 67.5 (14.3) 62.7 (15.6) 67.7 (15.3) 64.4 (15.7)
sex       
Male, n (%) 43 (48.3) 40 (61.5) 41 (60.3) 36 (48.6) 57 (64.0) 217 (56.4)
Weight, kg       
n (non-missing) 76 63 41 52 34 266
Mean (sD) 71.9 (21.1) 70.6 (15.7) 73.9 (12.0) 84.0 (19.1) 73.3 (13.4) 74.5 (17.9)
Patients with comorbidity requiring 
hospitalization or treatment (surgery/
chronic or current drug therapy), n (%)
72 (80.9) 52 (80.0) 61 (89.7) 60 (81.1) 82 (92.1) 327 (84.9)
Dccs, mean (sD) 1.7 (1.9) 2.5 (2.7) 3.7 (3.1) 1.9 (2.0) 2.4 (2.4) 2.4 (2.5)
Dccs, n (%)       
0 36 (40.4) 23 (35.4) 11 (16.2) 20 (27.0) 23 (25.8) 113 (29.4)
1–2 30 (33.7) 13 (20.0) 18 (26.5) 35 (47.3) 31 (34.8) 127 (33.0)
3–4 15 (16.9) 17 (26.2) 14 (20.6) 10 (13.5) 19 (21.3) 75 (19.5)
≥5 8 (9.0) 12 (18.5) 25 (36.8) 9 (12.2) 16 (18.0) 70 (18.2)
number of comorbidities by patient       
n (non-missing) 72 52 61 60 82 327
number, mean (sD) 2.0 (1.0) 2.8 (1.6) 3.2 (2.1) 2.1 (1.2) 2.5 (1.6) 2.5 (1.6)
comorbidity (≥10% of overall patients), 
n (%)
      
n 72 52 61 60 82 327
hypertension 34 (47.2) 30 (57.7) 28 (45.9) 38 (63.3) 43 (52.4) 173 (52.9)
Malignancy 22 (30.6) 13 (25.0) 29 (47.5) 11 (18.3) 26 (31.7) 101 (30.9)
Diabetes 20 (27.8) 13 (25.0) 15 (24.6) 11 (18.3) 25 (30.5) 84 (25.7)
cOPD 2 (2.8) 11 (21.2) 7 (11.5) 8 (13.3) 9 (11.0) 37 (11.3)
Renal insufficiency 8 (11.1) 5 (9.6) 14 (23.0) 0 (0.0) 9 (11.0) 36 (11.0)
liver disease 3 (4.2) 5 (9.6) 10 (16.4) 8 (13.3) 9 (11.0) 35 (10.7)
hospitalized within 90 days prior to the 
index hospitalization, n (%)
Yes 28 (31.5) 17 (26.2) 32 (47.1) 15 (20.3) 30 (33.7) 122 (31.7)
no 52 (58.4) 33 (50.8) 30 (44.1) 54 (73.0) 56 (62.9) 225 (58.4)
Unknown 9 (10.1) 15 (23.1) 6 (8.8) 5 (6.8) 3 (3.4) 38 (9.9)
Patient administered any antibiotics 
within 90 days prior to the index 
diagnosis, n (%)
Yes 29 (32.6) 19 (29.2) 21 (30.9) 1 (1.4) 48 (53.9) 118 (30.6)
no 43 (48.3) 21 (32.3) 32 (47.1) 50 (67.6) 33 (37.1) 179 (46.5)
Unknown 17 (19.1) 25 (38.5) 15 (22.1) 23 (31.1) 8 (9.0) 88 (22.9)
If yes, antibiotic class, n (%)
β-lactam antibacterials, penicillins 5 (17.2) 9 (47.4) 5 (23.8) 0 (0.0) 23 (47.9) 42 (35.6)
Other β-lactam antibacterials 12 (41.4) 8 (42.1) 5 (23.8) 1 (100) 13 (27.1) 39 (33.1)
Quinolone antibacterials 10 (34.5) 1 (5.3) 5 (23.8) 0 (0.0) 4 (8.3) 20 (16.9)
Other antibacterials 0 (0.0) 0 (0.0) 3 (14.3) 0 (0.0) 5 (10.4) 8 (6.8)
aminoglycoside antibacterials 0 (0.0) 1 (5.3) 0 (0.0) 0 (0.0) 2 (4.2) 3 (2.5)
sulfonamides and trimethoprim 2 (6.9) 0 (0.0) 1 (4.8) 0 (0.0) 1 (2.1) 4 (3.4)
all other therapeutic products 0 (0.0) 0 (0.0) 2 (9.5) 0 (0.0) 0 (0.0) 2 (1.7)
acquisition of cIaI, n (%)
hospital-acquired 48 (53.9) 42 (64.6) 38 (55.9) 55 (74.3) 56 (62.9) 239 (62.1)
health care–associated 41 (46.1) 23 (35.4) 30 (44.1) 19 (25.7) 33 (37.1) 146 (37.9)
Note: Percentages are calculated with numbers of patients for whom data were available as the denominator for each category as the denominator for each category.
Abbreviations: cIaI, complicated intra-abdominal infection; Dccs, Deyo-charlson comorbidity score.
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with 327 (84.9%) of 385 patients having at least one comor-
bidity that required hospitalization, chronic or ongoing drug 
therapy, or surgical treatment (Table 1).
Within the 90 days prior to index hospitalization, 122 
(31.7%) patients had been hospitalized at least once and 
118 (30.6%) had received antibiotics. Of those who had 
received prior antibiotics, the majority had received either 
β-lactam–based penicillin or another β-lactam–based anti-
bacterial (Table 1).
The majority of patients in this cIAI cohort underwent 
a surgical intervention (295/385, 76.6%), with the majority 
of those surgeries being for the purpose of source control of 
the infection (218/295, 73.9%). A second surgical interven-
tion to control the source infection was required by 20.2% 
of those who underwent surgery, and 13.3% required three 
or more surgical interventions. Of note, the proportion 
of patients who underwent surgery and required three or 
more surgical interventions to control the source infection 
was numerically higher in Brazil and Russia (22.0% and 
19.7%, respectively) than in other countries (≤10.0%), as 
shown in Table 2.
Pathogen characteristics
At least one bacterial pathogen was identified in 270 (70.1%) 
patients. Among the 454 bacterial pathogens isolated, 46 were 
isolated before the start of IAT, 309 were isolated within 0–6 
days of the start of IAT and 133 were isolated 7 days or more 
after the start of IAT. Of the 270 patients, 221 (81.9%) had a 
Gram-negative pathogen isolated, 92 (34.1%) had a Gram-
positive pathogen and 21 (7.8%) had an anaerobic pathogen 
(a patient could have more than one pathogen type identi-
fied; Figure 1 and Table S2). The most commonly isolated 
Gram-negative pathogens (≥10% of patients) were E. coli 
(47.0%), Klebsiella spp. (17.0%) and P. aeruginosa (11.1%); 
however, differences were noted across countries (Figure 1 
and Table S2). The most commonly isolated Gram-positive 
pathogens overall were Enterococcus spp. (20.0% of patients 
in the overall cIAI cohort), although again, differences were 
noted across countries.
MDR pathogens were isolated in 41.5% of all patients 
who had a pathogen identified, with the highest incidence 
observed in Russia and the lowest in Brazil and Italy (Fig-
ure 1 and Table S2). Among individual species, MDR iso-
lates were identified in 32 (25.2%) out of 127 patients for 
E. coli, 25 (54.3%) out of 46 patients for Klebsiella spp., 
9 (30.0%) out of 30 patients for P. aeruginosa, 27 (50.0%) 
out of 54 patients for Enterococcus spp., 12 (41.4%) out 
of 29 patients for Staphylococcus spp. and 13 (92.9%) out 
of 14 patients for Acinetobacter spp. In patients in whom 
any MDR pathogen was isolated, resistance was most 
common to penicillins either with or without β-lactamase 
inhibitors (63.4% and 73.2%, respectively), quinolones 
Table 2 summary of procedures performed during hospitalization for the index infection
Parameters Brazil 
(n=89)
France 
(n=65)
Italy 
(n=68)
Russia 
(n=74)
Spain 
(n=89)
Total 
(N=385)
Patients with procedures undertaken during 
hospitalization for the index infection, n (%)
      
surgical interventiona 77 (86.5) 41 (63.1) 47 (69.1) 68 (91.9) 62 (69.7) 295 (76.6)
1b 45 (58.4) 25 (61.0) 33 (70.2) 37 (54.4) 32 (51.6) 175 (58.3)
2b 15 (19.5) 6 (14.6) 10 (21.3) 18 (26.5) 20 (32.3) 69 (23.4)
≥3b 17 (22.1) 10 (24.4) 4 (8.5) 13 (19.1) 10 (16.1) 54 (18.3)
Mechanical ventilation 54 (60.7) 28 (43.1) 12 (17.6) 28 (37.8) 24 (27.0) 146 (37.9)
Other procedure 19 (21.3) 4 (6.2) 17 (25.0) 0 (0.0) 37 (41.6) 77 (20.0)
endoscopy 6 (6.7) 7 (10.8) 7 (10.3) 6 (8.1) 11 (12.4) 37 (9.6)
none 0 (0.0) 20 (30.8) 8 (11.8) 2 (2.7) 5 (5.6) 35 (9.1)
Tracheostomy 10 (11.2) 0 (0.0) 1 (1.5) 17 (23.0) 6 (6.7) 34 (8.8)
hemodialysis 11 (12.4) 9 (13.8) 3 (4.4) 3 (4.1) 4 (4.5) 30 (7.8)
number of surgical interventions to control the 
source infection
      
n 50 30 24 61 53 218
1 31 (62.0) 20 (66.7) 20 (83.3) 7 (60.7) 37 (69.8) 145 (66.5)
2 8 (16.0) 7 (23.3) 3 (12.5) 12 (19.7) 14 (26.4) 44 (20.2)
≥3 11 (22.0) 3 (10.0) 1 (4.2) 12 (19.7) 2 (3.8) 29 (13.3)
Notes: Percentages are calculated with numbers of patients for whom data were available as the denominator for each category as the denominator; total of percentages 
may exceed 100%. More than one procedure may apply for a single patient. asurgical interventions refer to open abdomen procedures. Percutaneous interventions, 
interventional radiology and laparoscopic procedures were recorded as “other procedures”, including those performed to control the infection. bn (%) of those undergoing 
a surgical intervention.
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(69.6%), aminoglycosides (64.3%), cephalosporins 
(62.5%), macrolides (33.0%), carbapenems (31.3%) and 
tetracyclines (21.4%).
IaT treatment patterns
In the cIAI cohort, 48.6% of patients (187/385) received a 
single antibiotic as their IAT, while the remaining 51.4% 
(198/385) received a combination of antibiotics. The mean 
(SD) duration of IAT was 11.1 (20.2) days. Notably, IAT 
duration was shorter in patients receiving monotherapy than 
in those receiving combination therapy (Table 3). Large 
inter-country variation was observed in the antibiotics used 
throughout the study. The most common agents used either 
as a monotherapy or as part of a combination therapy are 
presented in Table 3 (all agents used as part of any IAT 
therapy in ≥5% of the total population). Across all countries, 
the most frequent monotherapy IATs (≥5% of those receiv-
ing monotherapy) were β-lactams/β-lactamase inhibitors 
 (piperacillin–tazobactam, 33.2%; ampicillin–sulbactam, 
13.4%, amoxicillin–clavulanic acid, 5.3%) or β-lactams on 
their own (ceftriaxone, 10.2%; cefotaxime, 6.4%; merope-
nem, 5.3%). The most frequent combination IATs (≥5% 
of those receiving combination therapy) were ceftriaxone 
+ metronidazole (11.6%), ciprofloxacin + metronidazole 
(11.1%), meropenem + vancomycin and amikacin + ceftri-
axone + metronidazole (6.1% each).
The most common reasons for IAT discontinuation 
reported by physicians were cure (32.9%), perceived failure 
(28.5%), de-escalation (18.8%) and death (14.9%), as shown 
in Table 3. Notably, discontinuation due to cure was numeri-
cally higher in patients receiving combination therapy than 
monotherapy (39.3% vs 26.2%, respectively).
In the overall cIAI cohort, 37.9% received only the IAT. 
Meanwhile, 62.1% had a second line of treatment, 34.5% a 
third, 19.5% a fourth and 9.6% a fifth line. Most treatment 
lines given after IAT were monotherapies: 64.0% (153/239), 
Brazil (n=64)
A B
C D
E F
48.4% Escherichia coli
17.2% Klebsiella spp.
6.3% Pseudomonas aeruginosa
10.9% Enterobacter spp.
6.3% Acinetobacter spp.
4.7% Other gram-negative bacteria
31.3% Gram-positive bacteria
0.0% Anaerobic bacteria
France (n=48)
43.8% Escherichia coli
6.3% Klebsiella spp. 
10.4% Pseudomonas aeruginosa
6.3% Enterobacter spp. 
0.0% Acinetobacter spp. 
14.6% Other Gram-negative bacteria
39.6% Gram-positive bacteria
18.8% Anaerobic bacteria
Italy (n=44)
43.2% Escherichia coli
13.6% Klebsiella spp.
6.8% Pseudomonas aeruginosa
18.2% Enterobacter spp. 
2.3% Acinetobacter spp. 
6.8% Other gram-negative bacteria
40.9% Gram-positive bacteria
4.5% Anaerobic bacteria
Russia (n=43)
39.5% Escherichia coli
39.5% Klebsiella spp.
2.3% Pseudomonas aeruginosa
0.0% Enterobacter spp. 
14.0% Acinetobacter spp. 
7.0% Other Gram-negative bacteria
14.0% Gram-positive bacteria
0.0% Anaerobic bacteria
Spain (n=71)
54.9% Escherichia coli
12.7% Klebsiella spp. 
23.9% Pseudomonas aeruginosa
7.0% Enterobacter spp. 
4.2% Acinetobacter spp. 
21.1% Other Gram-negative bacteria
40.8% Gram-positive bacteria
14.1% Anaerobic bacteria
Total (N=270)
47.0% Escherichia coli
17.0% Klebsiella spp. 
11.1% Pseudomonas aeruginosa
8.5% Enterobacter spp. 
5.2% Acinetobacter spp. 
11.5% Other Gram-negative bacteria
34.1% Gram-positive bacteria
7.8% Anaerobic bacteria
Figure 1 Most common bacterial pathogens identified in specimen samples from patients in Brazil (A), France (B), Italy (C), Russia (D), spain (E) and overall (F).
Notes: Patients could have more than one pathogen type identified. Data missing for 22 patients in Brazil. Percentages are calculated as a proportion of those patients with 
≥1 bacterial pathogen identified.
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75.9% (101/133), 84.0% (63/75) and 48.6% (18/37) of the 
patients in the second to fifth treatment lines, respectively. 
Overall, the mean (SD) total number of days of antibiotic 
therapy, including all lines of treatment, was 26.3 (53.8) 
days (Table 4). This was shorter in cases of IAT success than 
IAT failure or indeterminate outcome. However, variation in 
overall treatment duration was observed across the different 
countries (Table 4).
clinical outcomes of IaT
IAT failure was identified in 263 (68.3%) patients in the over-
all cIAI cohort, with similar rates across all countries (Table 
4). Patients receiving monotherapy had numerically higher 
rates of IAT failure compared to those receiving combina-
tion therapy (70.6% vs 66.2%, respectively; Figure 2). IAT 
success and indeterminate outcomes were observed in 22.5% 
and 7.0%, respectively, of patients receiving monotherapy 
and in 28.8% and 5.1%, respectively, of patients receiving 
combination therapy.
For all patients, the overall mean (SD) length of hospi-
tal stay from admission to discharge was 28.8 (30.8) days. 
Length of hospital stay did not differ greatly by IAT treatment 
outcome, except in Brazil, where patients with IAT success 
had a numerically shorter length of hospital stay than those 
with IAT failure (Table 4). The overall in-hospital mortality 
rate was 40.8%, although this varied across the participating 
countries, being highest in Brazil and lowest in Spain and 
Italy. The 30-day post-discharge mortality rate was 41.0% 
(Table 4).
There was a numerically higher rate of IAT failure in 
patients with MDR pathogens identified (81.3%) than those 
without (62.7%) in the overall cohort; this was observed 
consistently across all participating countries except France, 
where the IAT failure rates in patients with or without an 
Table 3 characteristics of IaT overall and by country
Parameter Brazil 
(n=89)
France 
(n=65)
Italy 
(n=68)
Russia 
(n=74)
Spain 
(n=89)
Total 
(N=385)
Type of therapy, n (%)       
Monotherapy 48 (53.9) 25 (38.5) 34 (50.0) 26 (35.1) 54 (60.7) 187 (48.6)
combination therapy 41 (46.1) 40 (61.5) 34 (50.0) 48 (64.9) 35 (39.3) 198 (51.4)
IaT duration, days, mean (sD)       
all IaT 8.6 (8.1) 14.0 (45.9) 11.0 (7.8) 10.8 (7.4) 11.8 (9.1) 11.1 (20.2)
Monotherapy 8.5 (8.9) 5.7 (3.8) 10.7 (7.4) 6.9 (4.1) 11.6 (9.0) 9.2 (7.9)
combination therapy 8.6 (7.0) 19.2 (58.1) 11.3 (8.2) 13.0 (8.0) 12.0 (9.3) 12.8 (27.1)
Most common IaT given as a monotherapy or as a part of 
a combination therapy (≥5% of the total population), n (%)
      
Piperacillin–tazobactam 11 (12.4) 32 (49.2) 25 (36.8) 0 (0.0) 42 (47.2) 110 (28.6)
Metronidazole 23 (25.8) 15 (23.1) 19 (27.9) 41 (55.4) 12 (13.5) 110 (28.6)
ceftriaxone 6 (6.7) 11 (16.9) 4 (5.9) 38 (51.4) 2 (2.2) 61 (15.8)
Ciprofloxacin 23 (25.8) 5 (7.7) 7 (10.3) 2 (2.7) 9 (10.1) 46 (11.9)
amikacin 0 (0.0) 15 (23.1) 0 (0.0) 16 (21.6) 6 (6.7) 37 (9.6)
Meropenem 9 (10.1) 1 (1.5) 11 (16.2) 1 (1.4) 12 (13.5) 34 (8.8)
ampicillin + sulbactam 22 (24.7) 0 (0.0) 8 (11.8) 3 (4.1) 0 (0.0) 33 (8.6)
Vancomycin 10 (11.2) 7 (10.8) 5 (7.4) 0 (0.0) 8 (9.0) 30 (7.8)
cefotaxime 0 (0.0) 0 (0.0) 3 (4.4) 14 (18.9) 5 (5.6) 22 (5.7)
Imipenem 1 (1.1) 8 (12.3) 5 (7.4) 0 (0.0) 6 (6.7) 20 (5.2)
Reason for IaT discontinuation, n (%)a       
cure 20 (22.7) 29 (44.6) 27 (40.3) 24 (32.4) 26 (29.2) 126 (32.9)
Perceived clinical failure 49 (55.7) 9 (13.8) 15 (22.4) 17 (23.0) 19 (21.3) 109 (28.5)
De-escalation 4 (4.5) 17 (26.2) 14 (20.9) 5 (6.8) 32 (36.0) 72 (18.8)
Death 14 (15.9) 11 (16.9) 8 (11.9) 19 (25.7) 5 (5.6) 57 (14.9)
Isolation of a resistant pathogen 4 (4.5) 3 (4.6) 11 (16.4) 2 (2.7) 15 (16.9) 35 (9.1)
secondary infection requiring regimen change 6 (6.8) 3 (4.6) 3 (4.5) 12 (16.2) 4 (4.5) 28 (7.3)
switch to oral therapy 0 (0.0) 2 (3.1) 4 (6.0) 0 (0.0) 5 (5.6) 11 (2.9)
adverse event 0 (0.0) 1 (1.5) 2 (3.0) 0 (0.0) 3 (3.4) 6 (1.6)
Note: aPatient might report more than one reason for stopping IaT.
Abbreviation: IaT, initial antibiotic treatment.
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MDR pathogen identified were roughly similar (Figure 3). In 
the overall cohort of patients with an MDR pathogen identi-
fied, the in-hospital and 30-day post-discharge mortality rates 
were also slightly higher than in those with no MDR pathogen 
identified. However, this was not consistently reflected across 
countries (Table 4).
Univariate and multivariate factors 
associated with IaT failure
Factors associated with IAT failure identified by the uni-
variate (unadjusted) analysis (P≤0.25) for consideration in 
the multivariate analysis were age: country; intensive care 
unit (ICU) admission; DCCS; site-level resistance to third-
generation cephalosporins, third-generation carbapenems, 
or combined site-level resistance to both; patient-level pres-
ence of MDR pathogens; prior hospitalization within 90 
days prior to the index hospitalization and treatment with 
β-lactams within 90 days prior to the index hospitaliza-
tion (Table 5). Accounting for these confounding factors, 
a multivariate model was developed. The final model had a 
Hosmer–Lemeshow χ2 value of 1.3467 with five degrees of 
freedom (P=0.9301), indicating no evidence of lack of fit. 
The final model also had deviance and Pearson χ2 values of 
138.01 and 128.03 with 116 degrees of freedom (P=0.0799 
and P=0.2097), respectively, indicating no evidence to reject 
the fitted model. Using this model, three predictive factors 
with a statistically significant association with IAT failure 
(P≤0.05) were identified: patients admitted or transferred to 
an ICU setting during their index hospitalization (P=0.024), 
patient-level isolation of an MDR pathogen (P<0.001) and 
treatment with β-lactam antibiotics within 3 months prior to 
the index diagnosis (P=0.025).
Discussion
IAT treatment patterns, outcomes and potential risk fac-
tors for IAT failure in patients with health care-associated 
Table 4 Treatment outcome measures, overall and by country
Parameter Brazil 
(n=89)
France 
(n=65)
Italy 
(n=68)
Russia 
(n=74)
Spain 
(n=89)
Total 
(N=385)
IaT outcome, n (%)       
Failurea 70 (78.7) 42 (64.6) 42 (61.8) 53 (71.6) 56 (62.9) 263 (68.3)
success 18 (20.2) 20 (30.8) 22 (32.4) 19 (25.7) 20 (22.5) 99 (25.7)
Indeterminate 1 (1.1) 3 (4.6) 4 (5.9) 2 (2.7) 13 (14.6) 23 (6.0)
Treatment duration (all lines of 
therapy), mean (sD) days
18.0 (15.3) 19.7 (46.0) 24.3 (47.9) 26.2 (61.6) 41.0 (75.0) 26.3 (53.8)
Duration by IaT outcome, mean 
(sD) days
      
Failure 20.5 (16.3) 14.4 (12.2) 20.1 (12.0) 32.2 (72.0) 52.6 (92.1) 28.7 (55.8)
success 8.2 (3.4) 32.2 (81.0) 31.6 (83.1) 11.5 (5.7) 16.1 (14.4) 20.5 (53.9)
Indeterminate 15.0 (na) 9.7 (5.5) 27.8 (14.9) 7.5 (0.7) 29.3 (14.6) 24.0 (15.0)
lOs (from admission to discharge), 
mean (sD) days
22.2 (17.3) 28.5 (23.8) 34.3 (48.4) 19.6 (14.5) 39.2 (34.9) 28.8 (30.8)
lOs by IaT outcome, mean (sD) 
days
      
Failure 25.5 (17.8) 29.6 (27.8) 25.2 (14.9) 21.6 (16.1) 43.9 (39.2) 29.3 (26.0)
success 9.1 (6.3) 28.7 (13.9) 51.5 (80.4) 15.2 (7.2) 27.9 (26.7) 27.5 (42.4)
Indeterminate 22.0 (na) 13.0 (9.5) 34.3 (25.4) 8.0 (1.4) 36.2 (20.3) 29.7 (20.8)
In-hospital mortality rate, n (%) 50 (56.2) 30 (46.2) 18 (26.5) 40 (54.1) 19 (21.3) 157 (40.8)
With MDR pathogen, n/n (%) 15/20 (75.0) 8/23 (34.8) 5/14 (35.7) 16/22 (72.7) 6/33 (18.2) 50/112 (44.6)
Without MDR pathogen, n/n (%) 20/44 (45.5) 12/25 (48.0) 7/30 (23.3) 9/21 (42.9) 9/38 (23.7) 57/158 (36.1)
30-day mortality rate, n (%) 50 (56.2) 30 (46.2) 18 (26.5) 40 (54.1) 20 (22.5) 158 (41.0)
With MDR pathogen, n/n (%) 15/20 (75.0) 8/23 (34.8) 5/14 (35.7) 16/22 (72.7) 7/33 (21.1) 51/112 (45.5)
Without MDR pathogen, n/n (%) 20/44 (45.5) 12/25 (48.0) 7/30 (23.3) 9/21 (42.9) 9/38 (23.7) 57/158 (36.1)
number of days from initiation of 
IaT to patient’s death (within 30 
days of discharge), mean (sD)
19.6 (17.2) 18.7 (20.7) 15.8 (13.0) 18.4 (15.5) 41.6 (47.9) 21.5 (24.2)
Notes: aIAT failure defined as discontinuation of the antibiotic regimen for reasons other than cure/improvement in symptoms, including dose increase or addition of another 
antibiotic beyond 48 hours of treatment, in-hospital death of any cause or readmission due to recurrence of the same infection within 30 days of discharge. streamlining, 
de-escalation or switch to oral antibiotics was not considered as treatment failure.
Abbreviations: IaT, initial antibiotic treatment; lOs, length of hospital stay; MDR, multidrug resistant, na, not applicable.
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infections, including cIAI, were assessed with a view to 
presenting a practicable insight into clinical management 
across Brazil, France, Italy, Spain and Russia. This is one of 
the first studies to look at the real-world outcomes and treat-
ment patterns across these countries in patients with health 
care-associated cIAI.
Patient and disease characteristics and pathogen 
identification documented here were in line with the few 
other observational studies that have looked at clinical, 
microbiological and treatment profiles of community- and 
health care–acquired cIAIs.5,22 Importantly, the frequency 
of comorbidities and previous number of admissions 
were high in this cohort. The most commonly observed 
pathogens (E. coli, Klebsiella spp. and P. aeruginosa) 
were reflective of those that have previously been associ-
ated with cIAI in more stringently selected populations 
within clinical trials21,23 and those observed in surveil-
lance studies.9 Of note, the proportion of patients from 
whom anaerobes were isolated was heterogeneous, which 
may reflect differences in sampling and microbiological 
procedures.
Across all countries in this study, IAT failure was 
observed in over two-thirds of patients. Failure rates were 
high (>60%) in each individual country, with higher rates 
observed in Brazil and Russia. The percentage of patients 
with an indeterminate outcome was low across all countries 
and unlikely to have affected the results observed. The high 
rate of failure may be due, in part, to the patient population 
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Figure 2 clinical outcomes of initial antibiotic therapy in patients receiving (A) monotherapy or (B) combination therapy.
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included and the definition of IAT failure used. However, 
such criteria reflect real-world antibiotic use in this group 
of patients.
In critically ill patients, empiric IAT has an integral role in 
the success of treating health care-associated infections.16–19 
Appropriate IAT choice is an important contributing factor 
to the likelihood of treatment success.1 Treatment guidelines 
advise that IAT for IAI should comprise a spectrum covering 
possible etiological pathogens, including Gram-negatives and 
anaerobes.12,24 This can be monotherapy active against both or 
combination therapies that provide the coverage required. IAT 
should also be tailored to account for known local intrinsic 
resistance mechanisms of likely etiological pathogens and, 
in the health care-associated setting, coverage for P. aerugi-
nosa and Gram-positive bacteria such as Enterococcus spp. 
is recommended.1,25
In the present study, large inter-country variation was 
observed in the specific antibiotics used, potentially due to 
differences in the availability and cost of antibiotics across the 
different countries or the prescribing patterns accounting for 
local resistance patterns. However, from the relatively high 
level of IAT failure observed and the proportion of patients 
with perceived clinical failure requiring subsequent lines of 
antibiotic therapy, IAT selection in some of these patients 
might have been suboptimal, providing limited or compro-
mised efficacy against the subsequently identified pathogens.
With an ever-increasing prevalence of MDR pathogens 
isolated from cIAIs, antimicrobial resistance among health 
care-associated pathogens has been identified as one of the 
major challenges in the management of cIAI.7,9,22 In the 
present study, just under half of the patients with pathogens 
identified had an MDR pathogen isolated. This is consistent 
with the literature, which shows a higher proportion of MDR 
pathogens among health care-associated infections than 
community-acquired infections.6 The definition of MDR 
in this study was in line with that proposed in a European 
Center for Disease Prevention and Control and Centers for 
Disease Control and Prevention initiative.26 The multivariate 
analyses performed demonstrate that the presence of an MDR 
pathogen and treatment with β-lactam antibiotics within the 
3 months prior to index infection are associated with an 
increased risk of IAT failure. It is noteworthy that it was spe-
cifically pretreatment with β-lactam antibiotics and not any 
other pretreatment that was significantly associated with IAT 
failure. While it is expected that the use of previous antibiot-
ics would select patients with drug-resistant pathogens, the 
effect of previous β-lactam use was independent of isolation 
of an MDR pathogen. These data support the importance 
of understanding and interpreting treatment guidelines to 
account for patient history and the local epidemiology.14,16,27,28
In addition to high IAT failure rates, the overall mortality 
rates observed here were higher than the average mortality 
rates seen in other observational studies (typically around 
10% or less), which mostly included less-complicated com-
munity-acquired infections.5,22,29,30 However, it is recognized 
that the cause of death has not been analyzed and may not 
be related to the index infection.
Limitations of this study pertained mostly to its retrospec-
tive design, which limited data availability to information in 
the patient record and, given the relative ease of enrolling 
deceased vs living patients, may have favored the selection of 
a more severely ill patient population. Severity of illness may 
be reflected in the relatively high proportion of patients who 
were admitted or transferred to the ICU and may explain the 
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Table 5 statistical predictors of initial antibiotic treatment failure – univariate and multivariate analyses
Potential risk factors Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
age, years     
18–44a Reference 0.050b – –
45–64 1.42 (0.70, 2.89)  – –
≥65 2.14 (1.07, 4.26)  – –
gender     
Femalea Reference 0.785   
Male 0.94 (0.61, 1.45)    
country     
spaina Reference 0.093b – –
Brazil 2.17 (1.12, 4.22)  – –
France 1.08 (0.55, 2.09)  – –
Italy 0.95 (0.50, 1.83)  – –
Russia 1.49 (0.77, 2.89)  – –
number of days in hospital before the start of IaT     
0.7a Reference 0.393 – –
8–14 0.67 (0.35, 1.28)  – –
15–30 0.69 (0.31, 1.51)  – –
>30 0.50 (0.15, 1.69)  – –
IcU admission (initial admission or transfer)     
noa Reference <0.001b Reference –
Yes 2.31 (1.48, 3.59)  2.49 (1.13, 5.51) 0.024
Dccs     
0a Reference 0.080b – –
1–2 1.16 (0.68, 1.96)  – –
3–4 2.10 (1.08, 4.06)  – –
≥5 1.77 (0.92, 3.42)  – –
site-level resistance to third-generation 
cephalosporinsc
    
noa Reference 0.132b – –
Yes 0.99 (0.98, 1.00)  – –
site-level resistance to third-generation 
carbapenemsc
    
noa Reference 0.032b – –
Yes 0.99 (0.98, 1.00)  – –
combined site-level resistance to third-
generation cephalosporins and carbapenemsc
    
noa Reference 0.001b – –
Yes 0.98 (0.96, 0.99)  – –
Patient-level presence of MDR pathogen     
noa Reference <0.001b Reference –
Yes 2.58 (1.46, 4.58)  5.45 (2.05, 14.52) <0.001
hospitalized within 90 days prior to the index 
hospitalization
    
noa Reference 0.019b – –
Yes 1.78 (1.09, 2.91)  – –
Treated with β-lactam antibiotic within the past 
3 months
    
noa Reference 0.008b Reference –
Yes 2.03 (1.18, 3.52)  3.20 (1.15, 8.87) 0.025
Notes: In this analysis, treatment outcome is either failure or success/indeterminate. The logistic regression coding is: 1= failure, 0= success or indeterminate. aReference 
category. bVariables identified as significant in the univariate logistic regression analysis (P≤0.25) were analyzed by multivariate logistic regression analysis. Data shown are 
from the final model using the stepwise backward selection process; therefore, only significant data that remained in the final model for the multivariate analysis are shown. 
cOn-site level of antibiotic resistance of gram-negative isolates to third-generation cephalosporins, carbapenems or both combined.
Abbreviations: Dccs, Deyo-charlson comorbidity score; IaT, initial antibiotic treatment; IcU, intensive care unit; MDR, multidrug resistant.
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association of this factor with IAT failure during multivariate 
analysis, although this should be interpreted with caution due 
to differences in hospital requirements and practice patterns 
for admission to the ICU. Given a lack of consensus on the 
definition for IAT failure, the study used a composite defini-
tion, which included additional interventions for infection 
source control and death due to any cause. With the relatively 
high level of comorbid conditions in these patients and their 
underlying medical conditions, inclusion of all-cause death 
may have overestimated the rate of IAT failure and led to 
worse outcomes than those observed in other published 
literature in this area.
Despite these limitations, the present study provides a 
global, real-world insight into current treatment patterns 
for patients with cIAI, the impact of IAT failure in patients 
who have been treated according to current cIAI practice 
and the potential risk factors associated with IAT failure. 
These data reiterate the challenges presented when choosing 
IAT, as well as the need for ongoing epidemiological studies 
and communication between microbiologists and prescrib-
ing physicians that will assist in providing a more tailored 
approach to IAT selection. This study was unique in looking 
specifically at the risk factors associated with IAT failure 
and in using IAT failure as an endpoint. With the paramount 
importance of effective early antibiotic treatment in cIAI, 
a broader awareness of local resistance epidemiology and 
further understanding of the influence of these risk factors 
on IAT and overall clinical outcome will help guide IAT 
selection and cIAI management.
Data sharing
Upon request, and subject to certain criteria, conditions and 
exceptions (see https://www.pfizer.com/science/clinical-
trials/trial-data-and-results for more information), Pfizer will 
provide access to individual de-identified participant data 
from Pfizer-sponsored global interventional clinical studies 
conducted for medicines, vaccines and medical devices: 1) 
for indications that have been approved in the USA and/or 
European Union; or 2) in programs that have been terminated 
(ie, development for all indications has been discontinued). 
Pfizer will also consider requests for the protocol, data dic-
tionary and statistical analysis plan. Data may be requested 
from Pfizer trials 24 months after study completion. The 
de-identified participant data will be made available to 
researchers whose proposals meet the research criteria and 
other conditions, and for which an exception does not apply, 
via a secure portal. To gain access, data requestors must enter 
into a data access agreement with Pfizer.
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Supplementary materials
Table S1 Iecs and IRBs consulted
Center 
number
Name and address of IEC/IRB Date of approval
0101 conselho Municipal de saúde de Porto alegre (Porto alegre Municipal Board of health)
Ramiro Barcelos, 2350 – Porto alegre/Rs
90035-903 Brazil
2 December 2015
0102 local ethics committee for human Research of the PUc-campinas (c.e.P.s.h.P.)
Rod. Dom Pedro I, Km 136 – Pq. das Universidades – campinas – sP (são Paulo), Brazil
24 august 2015
0103 local ethics committee of santa casa de Misericórdia de Belo horizonte
Rua Domingos Vieira 590, Santa Efigênia
30.150-240, Mg (Minas gerais) Belo horizonte, Brazil
26 October 2015
0104 Pontifícia Universidade católica do Rio grande do sul (“PUcRs”)
Research, Innovation & Development Pro-rector’s Office
Partenon 90.619-900 Rs Porto alegre,
Brazil
15 november 2015
0201 comitato etico Università sapienza
azienda Policlinico Umberto I
Viale del Policlinico, 155
00162 Roma, Italy
12 February 2015
0202 comitato etico dell`IRccs Itituto nazionale per le Malattie Infettive lazzaro spallanzani di Roma
Via Portuense 292-00149 Rome, Italy
17 February 2015
0203 al comitato etico per la sperimentazione clinica della Provincia di Vicenza c/o Ospedale s. Bortolo viale 
Rodolfi 37
36100 Vicenza, Italy
10 april 2015
0204 comitato etico Indipendente dell’azienda Ospedaliero- Universitaria di Bologna, Policlinico s. Orsola-Malpighi
Padiglione 3 – Via albertoni, 15-40138 Bologna, Italy
4 March 2015
0205 spedali civili – Brescia
comitato etico Provinciale
Provincia di Brescia
P.le spedali civili, 1-25123 Brescia, Italy
14 January 2015
0206 comitato etico della Provincia Monza Brianza
Via Pergolesi, 33-20090 Monza, Italy
2 March 2015
0301 germans Trias i Pujol hospital
Research ethics committee
crta. De canyet, s/n – 08,916 Badalona, spain
13 January 2015
0302 clinical Research ethics committee of hospital Universitari Mútua de Terrassa
Plaza Dr Robert, 5 08221 Terrassa, Barcelona, spain
18 December 2014
0303 cRec – Parc de salut MaR
Dr aiguader, 88, 08003 Barcelona, spain
13 January 2015
0304 clinical Research ethics committee of hospital clínic de Barcelona Villarroel,  
170-08036 Barcelona, spain
12 January 2015
0305 coordinating Biomedical Research ethics committee of andalusia
hospital Universitario Virgen Macarena
2° Planta. avda. Dr Fedriani, 3
41071 sevilla, spain
12 December 2014
0306 Research ethics committee of the Principality of asturias c/ celestino Villamil s/n
33006 Oviedo, spain
29 January 2015
0501 Moscow city health Department, The state-Financed health care Institution Municipal clinical hospital no. 
12 ethics committee, 26 Bakinskaya st., Moscow 115516, Russia
6 February 2015
0502 eXPeRT ethics committee at sPB sBhI (st Petersburg state Budgetary health care Institution) city hospital 
no. 40
9 Borisova street, sestroretsk, st Petersburg 197706, Russia
19 January 2015
0503 The local ethics committee of the st Petersburg state Budgetary health Institution, Mariinskaya city hospital
liteyny ave, 56, st Petersburg, Russia
30 December 2014
0505 ethics committee, state Budgetary Institution of health care (sBIh) of novosibirsk Region (nR) city clinical 
hospital (cch) no. 25 of novosibirsk
630075, novosibirsk, 1a alexander nevsky street, Russia
16 February 2015
Abbreviations: Iec, independent ethics committee; IRB, institutional review board.
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Table S2 Bacterial pathogens identified in specimen samples, including multidrug-resistant organisms, overall and by country
Bacterial pathogena Brazil 
(n=67)b
France 
(n=65)
Italy 
(n=68)
Russia 
(n=74)
Spain 
(n=89)
Total 
(N=363)b
n 64 48 44 43 71 270
gram-negative, n (%)c 50 (78.1) 35 (72.9) 34 (77.3) 39 (90.7) 63 (88.7) 221 (81.9)
Escherichia coli 31 (48.4) 21 (43.8) 19 (43.2) 17 (39.5) 39 (54.9) 127 (47.0)
Klebsiella spp. 11 (17.2) 3 (6.3) 6 (13.6) 17 (39.5) 9 (12.7) 46 (17.0)
Pseudomonas aeruginosa 4 (6.3) 5 (10.4) 3 (6.8) 1 (2.3) 17 (23.9) 30 (11.1)
Enterobacter spp. 7 (10.9) 3 (6.3) 8 (18.2) 0 (0.0) 5 (7.0) 23 (8.5)
Acinetobacter spp. 4 (6.3) 0 (0.0) 1 (2.3) 6 (14.0) 3 (4.2) 14 (5.2)
Proteus spp. 1 (1.6) 1 (2.1) 0 (0.0) 1 (2.3) 4 (5.6) 7 (2.6)
Citrobacter spp. 0 (0.0) 1 (2.1) 1 (2.3) 0 (0.0) 2 (2.8) 4 (1.5)
Serratia spp. 0 (0.0) 1 (2.1) 0 (0.0) 2 (4.7) 1 (1.4) 4 (1.5)
Morganella morganii 1 (1.6) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
Haemophilus spp. 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Salmonella spp. 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 1 (0.4)
Other 1 (1.6) 2 (4.2) 2 (4.5) 0 (0.0) 7 (9.9) 12 (4.4)
gram-positive, n (%)c 20 (31.3) 19 (39.6) 18 (40.9) 6 (14.0) 29 (40.8) 92 (34.1)
Enterococcus spp. 8 (12.5) 15 (31.3) 8 (18.2) 5 (11.6) 18 (25.4) 54 (20.0)
Staphylococcus spp. 11 (17.2) 4 (8.3) 7 (15.9) 0 (0.0) 7 (9.9) 29 (10.7)
Streptococcus spp. 2 (3.1) 2 (4.2) 4 (9.1) 1 (2.3) 7 (9.9) 16 (5.9)
Other 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0) 1 (1.4) 2 (0.7)
anaerobic bacteria, n (%)c 0 (0.0) 9 (18.8) 2 (4.5) 0 (0.0) 10 (14.1) 21 (7.8)
Bacteroides spp. 0 (0.0) 6 (12.5) 2 (4.5) 0 (0.0) 7 (9.9) 15 (5.6)
Clostridium spp. 0 (0.0) 2 (4.2) 0 (0.0) 0 (0.0) 2 (2.8) 4 (1.5)
Prevotella spp. 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 1 (0.4)
Other bacterial agent, n (%)c 1 (1.6) 2 (4.2) 0 (0.0) 0 (0.0) 3 (4.2) 6 (2.2)
Multidrug-resistant pathogen, n (%)c       
Yes 20 (31.3) 23 (47.9) 14 (31.8) 22 (51.2) 33 (46.5) 112 (41.5)
no 44 (68.8) 25 (52.1) 30 (68.2) 21 (48.8) 38 (53.5) 158 (58.5)
Missing 25 17 24 31 18 115
Fungal pathogen, n (%)d 2 (3.0) 8 (12.3) 5 (7.4) 0 (0.0) 15 (16.9) 30 (8.3)
Notes: aPatients could have more than one pathogen type identified. bData missing for 22 patients in Brazil. cPercentages are calculated as a proportion of those patients with 
≥1 bacterial pathogen identified. dPercentages are calculated as a proportion of the overall population.
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